

Risk of rare blood clotting much higher in COVID-19 than for vaccines

April 15 2021



Credit: CC0 Public Domain

Researchers at the University of Oxford have today reported that the risk of the rare blood clotting known as cerebral venous thrombosis (CVT) following COVID-19 infection is around 100 times greater than normal, several times higher than it is post-vaccination or following influenza.

The study authors, led by Professor Paul Harrison and Dr. Maxime Taquet from Oxford University's Department of Psychiatry and the

NIHR Oxford Health Biomedical Research Centre, counted the number of CVT cases diagnosed in the two weeks following diagnosis of COVID-19, or after the first dose of a [vaccine](#). They then compared these to calculated incidences of CVT following influenza, and the background level in the general population.

They report that CVT is more common after COVID-19 than in any of the comparison groups, with 30% of these cases occurring in the under 30s. Compared to the current COVID-19 vaccines, this risk is between 8-10 times higher, and compared to the baseline, approximately 100 times higher.

The breakdown comparison for reported cases of CVT in COVID-19 patients in comparison to CVT cases in those who received a COVID-19 vaccine is:

- In this study of over 500,000 COVID-19 patients, CVT occurred in 39 in a million patients.
- In over 480,000 people receiving a COVID-19 mRNA vaccine (Pfizer or Moderna), CVT occurred in 4 in a million.
- CVT has been reported to occur in about 5 in a million people after first dose of the AZ-Oxford COVID-19 vaccine.
- Compared to the mRNA vaccines, the risk of a CVT from COVID-19 is about 10 times greater.
- Compared to the AZ-Oxford vaccine, the risk of a CVT from COVID-19 is about 8 times greater.

An important factor that requires further research is whether COVID-19 and vaccines lead to CVT by the same or different mechanisms. There may also be under-reporting or mis-coding of CVT in medical records, and therefore uncertainty as to the precision of the results. Full data are available from osf.io/a9jdq/.

More information: Cerebral venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID-19 cases and a comparison with 489,871 people receiving a COVID-19 mRNA vaccine.

osf.io/a9jdq/

Provided by University of Oxford

Citation: Risk of rare blood clotting much higher in COVID-19 than for vaccines (2021, April 15) retrieved 6 May 2024 from <https://medicalxpress.com/news/2021-04-rare-blood-clotting-higher-covid-.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.